New Rx Option for Neuromyelitis Optica Spectrum Disorder?

Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.
Medscape Medical News